Cephalon, Inc.

NASDAQ:CEPH ISIN:US1567081096

Cephalon, Inc. (NASDAQ:CEPH) is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in four core therapeutic areas: central nervous system (CNS), pain, oncology and inflammatory disease.  
 

News

Mesoblast Limited (ASX:MSB) Received Licensing Executives Society 2011 Deals of Distinction(TM) Award

🕔10/20/2011 10:21:00 AM 6798

Mesoblast Limited (ASX:MSB) and its strategic alliance partner Cephalon Inc. were today awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction(TM) Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector.

Read Full Article

Mesoblast Limited (ASX:MSB) Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks

🕔9/5/2011 8:36:00 AM 7140

Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks.

Read Full Article

Mesoblast Limited (ASX:MSB) in Position of Considerable Strength

🕔8/24/2011 10:00:00 AM 6513

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided its full year financial results. The company stated that it had substantial funds of A$263.2 million at 30 June 2011. Mesoblast recorded revenue and other income of A$120.9 million and a profit before tax of A$92.2 million.

Read Full Article

Mesoblast Limited (ASX:MSB) Receive FDA Clearance for Phase 3 Bone Marrow Transplant Trial

🕔7/7/2011 9:23:00 AM 6323

Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers. FDA clearance was obtained within the 30-day minimum time period after Mesoblast filed its Phase 3 Investigational New Drug submission.

Read Full Article

Mesoblast Limited (ASX:MSB) Revascor Increases Blood Supply to Damaged Heart Muscle

🕔6/9/2011 9:39:00 AM 8580

Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.

Read Full Article

Mesoblast Limited (ASX:MSB) Update On Valeant (NYSE:VRX) Proposal To Cephalon (NASDAQ:CEPH)

🕔4/7/2011 9:19:00 AM 7157

Mesoblast Limited (ASX:MSB) (PINK:MBLTY) wishes to inform the market that the Board of its strategic partner Cephalon Inc. (NASDAQ:CEPH) has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc (NYSE:VRX) to acquire its issued share capital or certain assets.

Read Full Article

Mesoblast Limited (ASX:MSB) Statement On Valeant (TSE:VRX) Proposal To Cephalon (NASDAQ:CEPH)

🕔3/31/2011 5:50:09 PM 6710

Mesoblast Limited (ASX:MSB) (PINK:MBLTY), has received a number of enquiries from shareholders and analysts regarding yesterday's announcement by Mesoblast's strategic partner Cephalon Inc. (NASDAQ:CEPH) that it had received an unsolicited proposal from Valeant Pharmaceuticals International Inc (TSE:VRX) to acquire Cephalon's issued share capital or certain assets. Mesoblast continues to maintain a close dialogue with Cephalon.

Read Full Article

Mesoblast Limited (ASX:MSB) Release Half Year Financial Report To 31 Dec 2010

🕔2/28/2011 5:17:00 PM 4677

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today reported its half year results for the period ended 31 December 2010. At the reporting date, Mesoblast recorded funds of $140.6 million but has since nearly doubled its cash reserves to $279 million after an equity purchase by global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH) that brings its total Mesoblast holding to 19.99%.

Read Full Article

Mesoblast Limited (ASX:MSB) Issues New Equity To Cephalon Inc. (NASDAQ:CEPH), Receives Further Cash Injection

🕔2/14/2011 9:43:53 AM 4926

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported that it had issued an additional 24,702,056 ordinary shares to global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH), and received an additional cash injection of A$139 million. Mesoblast's total cash reserves are now approximately A$280 million.

Read Full Article

Mesoblast (ASX:MSB) And Cephalon (NASDAQ:CEPH) Alliance Highlighted At JP Morgan Healthcare Conference

🕔1/12/2011 9:58:33 AM 5070

The strategic alliance between regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), and global biopharmaceutical company, Cephalon Inc. (NASDAQ:CEPH), was highlighted at the 29th annual JP Morgan Healthcare Conference in San Francisco yesterday.

Read Full Article
###

10,699 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 26) (Last 30 Days: 70) (Since Published: 10699) 

Company Data

    Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.cephalon.com